Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Smart Cancer Screening vs. Full-Body MRI & Galleri
Fishtown Medicine•8 min read
4.96 (124)

Smart Cancer Screening vs. Full-Body MRI & Galleri

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated November 8, 2026
On This Page
  • Why do we take cancer screening forward from population guidelines without falling for wellness hype?
  • Tier 1: What does a high-precision, personal organ-specific screening calendar look like?
  • Tier 2: How do Whole-Body MRI (Prenuvo / Ezra) and Galleri (MCED) perform in 2026 studies?
  • 1. Commercial Whole-Body Screening MRI (Prenuvo, Ezra, and Similar)
  • 2. The Galleri Multi-Cancer Blood Test (PATHFINDER 2 & NHS-Galleri 2026)
  • Metabolic & Genetic Defense: Making Your Body Hostile to Cancer
  • Guidance from the Clinic
  • Common Questions
  • Can a negative Galleri blood test replace my colonoscopy, mammogram, HPV, or PSA test?
  • What happens if a Galleri test comes back positive ("Cancer Signal Detected")?
  • What happens per 1,000 healthy adults who get a commercial whole-body MRI?
  • Why shouldn't never-smokers get a screening low-dose chest CT (LDCT)?
  • ✦Key Takeaways
  • Related at Fishtown Medicine
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

Only five cancers (colorectal, breast, cervical, prostate, and eligible smoker lung cancer) have screening tests proven in randomized trials to reduce cancer deaths. Our N-of-1 calendar upgrades those five screens first: colonoscopy at age 45 (or age 40 / 10 years before a first-degree relative's diagnosis, with endoscopist ADR >= 35%; NordICC per-protocol -50% mortality), baseline PSA at age 40-45 with pre-biopsy MRI (GÖTEBORG-2 halves Gleason 6 overdiagnosis; ERSPC 23-year RR 0.87), 3D mammography plus personalized MRI in extremely dense breasts (DENSE trial), primary HPV testing, targeted dermatoscopic skin exams in high-risk adults, and low-dose chest CT strictly for >= 20 pack-year smokers (never in never-smokers, where NNS is 6,162 vs. 353 and Taiwan's CT push caused a 6-fold Stage 0-I surge with zero mortality drop). Commercial whole-body MRIs ($1,500-$2,500) flag findings in 78% of healthy adults, critical/indeterminate findings in 32.1%, and actionable non-malignant findings in 14.8% (triggering ~86 follow-up workups and ~31 procedures per 1,000 scanned) for a 1.4% to 1.57% cancer yield with zero mortality data (Ahsan 2026; Martins da Fonseca 2026; Cochrane 2026). Meanwhile, the Galleri blood test has 99.5%-99.64% specificity and 60.3% PPV in PATHFINDER 2 (Nabavizadeh Nat Med 2026, n = 32,007), but its Stage I sensitivity is only 16.8%, its negative likelihood ratio is 0.61 (61% of 1-year cancers occur after a negative test), and the 142,250-adult NHS-Galleri randomized trial missed its primary endpoint of reducing Stage III-IV cancers (IRR 1.03, P = 0.63, Sasieni NEJM 2026). Neither test ever replaces Tier 1 organ screening.

TL;DR: Only five cancer screens (colon, breast, cervix, prostate, and smoker lung) are proven in clinical trials to save lives. A smart plan upgrades those five tests first before adding blood tests or full-body scans.

  1. Lock in your 5 core organ screens first: Start colonoscopy at age 45 (or age 40 if a close relative had colon cancer, using a doctor with a polyp detection rate of 35% or higher). Get a baseline PSA blood test at age 40 to 45 paired with a prostate MRI before any biopsy. Use 3D mammograms plus breast MRI for very dense breasts, primary HPV swabs, skin checks for high-risk adults, and low-dose lung CT only if you smoked 20+ pack-years.
  2. Know what Galleri catches and misses: Galleri has a very low false-alarm rate (under 0.5%), and about half to 60% of positive tests find a cancer. However, it misses 83% of Stage I cancers, 61% of cancers found within a year happened in people who tested negative, and the 142,250-person NHS-Galleri trial did not cut combined Stage III and IV cancers. Never skip a colonoscopy or mammogram because a Galleri test was normal.
  3. Know the trade-offs of whole-body MRI: Scanning 1,000 healthy adults flags 780 with an abnormal spot and 320 with an unclear finding while finding cancer in 14 to 16 people (about 1.5%). We save whole-body MRI for high-risk gene carriers or strong family histories and use strict radiology rules to avoid needless biopsies.

A 46-year-old trial lawyer in Rittenhouse came to me ready to spend $3,450 on a commercial whole-body MRI plus a Galleri blood test because his father had died of colon cancer at 54. At the same time, he had been putting off his first colonoscopy because he thought the blood test and MRI would cover him. We walked through why a negative Galleri test misses 83% of Stage I cancers, missed 61% of 1-year cancers in PATHFINDER 2, and spots zero colon polyps. His father's cancer at 54 meant his own colonoscopy was already two years overdue (age 40, or 10 years before his father's diagnosis). That afternoon we booked his colonoscopy with a GI doctor whose polyp detection rate is over 42%. The doctor removed two 12 mm polyps on the spot and saved him $3,450 of false reassurance.

Why do we take cancer screening forward from population guidelines without falling for wellness hype?

Population rules (USPSTF) are built for 300 million average people. Commercial ads sell $2,500 scans as a shortcut around proven care. Our personal plan upgrades your five life-saving organ screens using your family tree, genes, and quality scores. We pair every optional test with clear math so you never trade missed early cancers for needless biopsies.

Only five cancers (colon, breast, cervix, prostate, and smoker lung) have randomized trial proof that screening cuts cancer deaths (Rubin JAMA 2026). Together they cause about 30% to 35% of US cancer deaths. The other 65% to 70% (pancreas, ovary, liver, stomach, kidney, and blood cancers) have no population screening trials. That gap is why patients ask about blood tests and whole-body MRI, and why you deserve an unconflicted doctor who shares the numbers on both.

Evidence-based cancer screening comparison showing the 5 organ screens with RCT mortality proof, outcomes per 1,000 healthy adults scanned with whole-body MRI, and Galleri sensitivity by stage in PATHFINDER 2 and NHS-Galleri
Figure: Randomized trials prove lower cancer deaths for five organ screens (NordICC, ERSPC 23-Yr, DENSE, NLST/NELSON), while 1,000 whole-body MRIs trigger ~321 unclear findings and ~31 procedures for 14-16 cancers (Ahsan 2026; Martins da Fonseca 2026), and Galleri misses 61% of 1-year cancers in PATHFINDER 2 (NLR 0.61) and missed its Stage III-IV goal in NHS-Galleri (IRR 1.03, Sasieni NEJM 2026).

Tier 1: What does a high-precision, personal organ-specific screening calendar look like?

Before spending money on commercial blood tests or whole-body magnets, we upgrade your five core organ screens from insurance minimums to precision care:

Organ & TargetStandard Population GuidelineFishtown Medicine Proactive Upgrade & Evidence Nuance
ColorectalAge 45-75 (USPSTF Grade B 45-49, Grade A 50-75: colonoscopy q10y or yearly FIT; COLONPREV Lancet 2025 showed 10-yr FIT non-inferiority; 2026 ACS puts blood tests second-line only).Average risk: Start at 45. Family history (1 first-degree relative < 60 with CRC/advanced polyp, or >= 2 at any age): Start at age 40 or 10 years before the youngest relative, repeating every 5 years (if 1 relative >= 60, start at 40 on standard intervals, NCCN 2026). Require endoscopist ADR >= 35% (>= 40% men, >= 30% women), cecal reach >= 95%, and withdrawal >= 8 min (Rex AJG 2024; each +1% ADR cuts interval CRC by 3% and fatal CRC by 5%, Corley NEJM 2014; NordICC per-protocol -50% deaths, Bretthauer NEJM 2022).
ProstateUSPSTF Grade C shared choice aged 55-69; AUA 2026 baseline at 45-50.Draw a baseline PSA at age 45-50 (or 40-45 for Black men, BRCA2 carriers, or strong family history). In PROBASE (Eur Urol 2024), PSA < 1.5 ng/mL at age 45 marks very low 5-year risk (< 1.0 ng/mL retest q2-4y; 1-3 ng/mL q1-2y). If PSA is high, check PSA density + pre-biopsy mpMRI (or PRISM biparametric MRI, JAMA Oncol 2026), which halves Gleason 6 overdiagnosis (GÖTEBORG-2, Hugosson NEJM 2022). The 23-year ERSPC follow-up (Roobol NEJM 2025) proved a 13% drop in prostate cancer deaths (RR 0.87, 456 invited / 12 diagnosed per death prevented).
Breast & Dense BreastsMammogram every 2 years aged 40-74 (USPSTF 2024); risk check by age 25 (ACR).3D mammograms (DBT) starting at 40 (~83 callbacks and 5.8 cancers found per 1,000 vs. 103-116 callbacks and 5.1-5.3 cancers with 2D; ~82% of recalls end without biopsy, including ~71% benign BI-RADS 1/2 and 11.4% BI-RADS 3, Lee BCSC 2023 / NMD 2024). Dense breasts (Category C/D) nuance: NCCN v1.2026 recommends breast MRI starting at 50 (consider from 40) for extremely dense Category D breasts (DENSE trial Bakker NEJM 2019: full-protocol MRI halved interval cancers from 5.0 to 2.5 per 1,000 ITT, and 0.8/1,000 in MRI attendees; in the UK BRAID RCT, Gilbert Lancet 2025, abbreviated MRI [17.4/1,000] and CEM [19.2/1,000] caught 4x more cancers than automated ultrasound [4.2/1,000]), while USPSTF (I statement) and ACP 2026 note mortality data are pending. We match added MRI or CEM to Category D or high-risk Category C (relative risk >= 2, Tosteson 2026).
Cervical & HPVPap q3y (21-29); primary HPV q5y preferred (30-65, WPSI / ACOG 2026).Primary HPV testing every 5 years (ages 30-65) (with FDA-cleared self-collected vaginal HPV swabs every 3 years as an option, Holt JAMA Intern Med 2026) plus Gardasil 9 vaccine (through age 45). Catches and treats precancer (CIN) before cancer forms.
Skin / MelanomaUSPSTF Grade I (not enough evidence for routine checks in low-risk adults).Why guidelines are cautious: Mass skin screening carries an estimated ~60% melanoma overdiagnosis rate (Joshi JAMA 2025) and showed no drop in deaths in Germany's national program (Hübner JAMA Derm 2026). Our rule: We focus every 6-to-12-month dermatoscopic checks on high-risk adults (past/family melanoma, atypical moles, fair skin/blistering sunburns, immune suppression, older White men, or pre-BBL/MOXI laser checks, Straub AAFP 2026), where dermoscopy cuts benign biopsies down to ~4:1.
Lung (Eligible Smokers Only)Yearly LDCT for ages 50-80 with >= 20 pack-years (USPSTF: current or quit < 15y; ACS 2023 drops the years-since-quit limit, Wolf 2023).Screen eligible >= 20 pack-year smokers (NLST -20% and NELSON -24% lung cancer deaths; Lung-RADS halves false positives). Never order screening LDCT in never-smokers: Modeling shows 6,162 average-risk never-smokers must be screened to prevent 1 death vs. 353 smokers (Xu Lancet Reg Health 2026). In Taiwan's TALENT study (Chang 2024), 96.5% of cancers found were Stage 0-I (mostly AIS/MIA), and CT promotion in Taiwanese women caused a 6-fold surge in early diagnoses with zero drop in late cancer or deaths (Gao, Wen & Welch JAMA Intern Med 2022). Instead, test home radon (fix if >= 4.0 pCi/L, EPA).

Tier 2: How do Whole-Body MRI (Prenuvo / Ezra) and Galleri (MCED) perform in 2026 studies?

Both whole-body MRI and Galleri are optional Tier 2 layers. Neither has randomized trial proof that it cuts cancer deaths, and a normal result on either test gives far less protection than most people think (Davenport & Reeder JAMA June 2026).

1. Commercial Whole-Body Screening MRI (Prenuvo, Ezra, and Similar)

Four pooled reviews (Kwee & Kwee JMRI 2019, n = 5,373; Gibson et al., BMJ 2018, n = 27,643; Ahsan et al., JGIM 2026, n = 18,043; and Martins da Fonseca et al., European Radiology 2026, n = 9,024) show what happens when 1,000 healthy adults get a whole-body MRI:

  • 780 per 1,000 (78.0%) have at least one abnormal finding flagged (Ahsan 2026).
  • 320 per 1,000 (32.1%) have a serious or unclear finding (Kwee 2019; in a 2026 ONCO-RADS study by Ali et al., 42.2% had an ONCO-RADS 3 or higher spot while cancer was 0.9%).
  • 150 per 1,000 (14.8%) have an actionable non-cancer finding, which triggers 86 follow-up scans or lab workups (58.2%) and 31 invasive procedures (20.8%) (Ahsan 2026).
  • 14 to 16 per 1,000 (1.4% to 1.57%) are diagnosed with cancer (Ahsan 2026; Martins da Fonseca 2026), with zero randomized mortality data to show how many are life-saving catches versus harmless overdiagnosis (Chen et al., Cochrane 2026).
  • The pancreatic cyst, cost, and biopsy cascade: In the largest screening MRI study to date (Wong et al., JAMA Network Open 2026, n = 21,651), 7.0% of healthy adults had incidental pancreatic cysts (rising to 20.8% at age 80 and up). Only 0.08% had cysts over 3 cm, yet about 1,500 people entered years of scan follow-up. In Germany's SHIP study, sharing whole-body MRI findings raised 2-year outpatient costs by 11.6% (Schmidt BMJ Open 2022) and raised benign biopsies by 39% (rate ratio 1.39, Richter Eur J Epidemiol 2020). At the same time, 2.8% of scans had false-negative results that missed colon, breast, and thyroid cancers (Basar Eur J Radiol 2021).
  • When whole-body MRI is endorsed (NCCN 2026): NCCN recommends yearly whole-body MRI for hereditary syndromes like Li-Fraumeni (TP53), where cancer yield is about 7% (versus 1.5% in the general public, Ballinger JAMA Oncol 2017). For the general public, the American College of Preventive Medicine (Choosing Wisely), a 2026 AJR Expert Panel, and a June 2026 JAMA editorial advise against routine scans.

Longevity Medicine

A personalized longevity strategy starts with knowing your real baselines.

Start Your Longevity Assessment

2. The Galleri Multi-Cancer Blood Test (PATHFINDER 2 & NHS-Galleri 2026)

Five landmark trials (CCGA3, PATHFINDER, SYMPLIFY, PATHFINDER 2, and NHS-Galleri) map how cell-free DNA methylation testing performs:

Study & PopulationSpecificitySensitivity (All Cancers & By Stage)Positive Predictive Value (PPV) & Origin (CSO)Key Clinical Takeaway
CCGA3 (Klein Ann Oncol 2021, n = 4,077 case-control)99.5%Overall: 51.5%
Stage I: 16.8% (Stage II: 40.4%, Stage III: 77.0%, Stage IV: 90.1%)
Case-control (N/A)
Origin (CSO): 88.7%
Misses 83.2% of Stage I cancers (and 95% of Stage II prostate cancers).
PATHFINDER (Schrag Lancet 2023, n = 6,662 aged >= 50)99.1%12-month episode: 29.5%38.0% (43.1% refined assay)
Origin: 85% first / 97% top-2
False positives took a median of 162 days of scans and procedures to clear.
SYMPLIFY (Nicholson Lancet Oncol 2023, n = 5,461 with symptoms)98.4%Overall: 66.3% (Stage I: 24.2%; prostate: 9.1%)75.5% (6.7% base rate)
Origin: 84.8%
Higher yield when symptoms are already present.
PATHFINDER 2 (Nabavizadeh Nat Med 2026, n = 32,007 aged >= 50)99.64%All cancers:** 39.3% (54.9% without breast/prostate)
12 deadly cancers: **69.8%
60.3% PPV**
Origin (CSO): **91.3%
Negative Likelihood Ratio = 0.61: 61% of 1-year cancers (267 / 440) happened in people who tested negative (~5 found, ~4 false positives, ~8 missed per 1,000).
NHS-Galleri RCT (Sasieni NEJM Oct 2026; Neal Nat Med 2026, n = 142,250 aged 50-77, 3 rounds)99.50% to 99.60%All cancers: 26.7% to 37.2% (melanoma: 2.5%)Round 1 -> 2 -> 3 PPV: 58.0% -> 50.4% -> 45.8%
Origin: 91.1%-93.6%
Missed primary goal of cutting Stage III-IV cancers in the 12 target types (IRR 1.03, 95% CI 0.92-1.14, P = 0.63; all staged cancers IRR 1.05). Fewer Stage IV cases (341 vs. 394; RR 0.86 overall, RR 0.74 Round 3) were offset by more Stage III cases (360 vs. 287).

Metabolic & Genetic Defense: Making Your Body Hostile to Cancer

  1. Map family genes early: When your family tree shows breast cancer under 50, triple-negative breast cancer, ovarian or pancreatic cancer at any age, colon or uterine clustering, or several affected relatives on one side, we order medical gene testing (BRCA1/2, PALB2, ATM, CHEK2, Lynch MLH1/MSH2/MSH6/PMS2, APC, TP53). A positive variant changes your whole schedule. Lynch carriers start colonoscopies in their 20s, BRCA carriers alternate mammograms and breast MRI every 6 months, and Li-Fraumeni TP53 carriers get NCCN-endorsed whole-body MRI.
  2. Lower high insulin (IGF-1) and belly fat: High insulin and visceral belly fat (100 cm2 or more on DEXA) raise the risk of at least 13 cancers (colon, breast, uterine, pancreas, liver, kidney) by turning on tumor insulin and IGF-1 growth switches. Keeping fasting insulin below 6 to 8 uIU/mL, hs-CRP below 1.0 mg/L, alcohol low, and muscle mass high protects every organ at once.

Guidance from the Clinic

Dr. Ash
"A patient should never buy a $950 blood test or a $2,500 whole-body MRI thinking it lets them skip a colonoscopy or mammogram. In PATHFINDER 2, 61% of cancers diagnosed within a year happened in people whose Galleri test was negative, and colonoscopy is the only test that removes precancerous polyps on the spot. We lock in high-precision organ screening first. When your family history justifies adding Galleri or an MRI-DWI scan, we quarterback the results so a benign cyst never spirals into a needless biopsy."
✦

Key Takeaways

  1. Complete & Upgrade Your 5 Mortality-Proven Organ Screens First: Colonoscopy (age 45, or 40 / 10y early for family history, with endoscopist ADR >= 35%, NordICC -50% per-protocol mortality), risk-adapted PSA at 40-50 + pre-biopsy mpMRI (GÖTEBORG-2; ERSPC 23-yr RR 0.87), 3D mammography + personalized dense-breast MRI (DENSE trial), primary HPV testing (ages 30-65), high-risk dermatoscopic skin exams, and >= 20 pack-year smoker LDCT are the only screens proven to save lives.
  2. Know Galleri's 2026 Trial Reality (PATHFINDER 2 & NHS-Galleri): 99.5%-99.64% specificity and 45.8%-60.3% PPV, paired with 16.8% Stage I sensitivity, a 0.61 negative likelihood ratio (61% of 1-year cancers missed after a negative test), and a missed primary Stage III-IV endpoint (IRR 1.03, P = 0.63) in NHS-Galleri.
  3. Know Whole-Body MRI's 1,000-Person Funnel: ~320 indeterminate findings, ~86 follow-up workups, and ~31 procedures per 1,000 adults scanned for 14 to 16 cancers (1.4%-1.57%) and zero mortality proof (Cochrane 2026). Reserve for hereditary syndromes (Li-Fraumeni ~7% yield) or triage with ONCO-RADS and ACR cutoffs.

Related at Fishtown Medicine

  • What the NHS-Galleri Trial Showed (And What It Means for Your Screening)
  • Grail Galleri Liquid Biopsy Guide
  • Boutique Whole-Body Scans & The Friday-Afternoon Incidentaloma Triage Guide
  • Colorectal Cancer Screening: Colonoscopy vs. FIT, Cologuard & Shield
  • PSA & Multiparametric Prostate MRI Screening
  • Mammogram Callbacks (BI-RADS 0) & Dense Breasts

Scientific References

  1. Multi-Cancer Early Detection (CCGA3, PATHFINDER, PATHFINDER 2, NHS-Galleri): Klein EA, Richards D, Cohn A, et al. (CCGA3). Ann Oncol. 2021;32(9):1167-1177; Schrag D, Beer TM, McDonnell CH 3rd, et al. (PATHFINDER). Lancet. 2023;402(10409):1251-1260; Nabavizadeh N, McDonnell C, Kurbegov D, et al. (PATHFINDER 2). Nat Med. 2026; Sasieni P, Johnson P, Round T, et al. (NHS-Galleri Trial). N Engl J Med. 2026; and Neal RD, Dolly S, Johnson P, et al. Nat Med. 2026.
  2. Whole-Body MRI Meta-Analyses, Cohorts & Editorials: Kwee RM, Kwee TC. J Magn Reson Imaging. 2019;50(5):1489-1503; Ahsan MD, Frontera N, Gurram A, et al. J Gen Intern Med. 2026; Martins da Fonseca J, Trennepohl T, Pinheiro LG, et al. Eur Radiol. 2026; Wong P, Pollini T, Hernandez S, et al. JAMA Netw Open. 2026; Chen Z, Johansson M, Albarqouni L, et al. Cochrane Database Syst Rev. 2026; and Davenport MS, Reeder SB. JAMA. 2026.
  3. High-Precision Organ Screening (NordICC, ADR, ERSPC 23-Yr, GÖTEBORG-2, DENSE, Never-Smoker LDCT): Bretthauer M, Løberg M, Wieszczy P, et al. (NordICC). N Engl J Med. 2022;387(17):1547-1556; Corley DA, Jensen CD, Marks AR, et al. N Engl J Med. 2014;370(14):1298-1306; Roobol MJ, de Vos II, Månsson M, et al. (ERSPC 23-Year). N Engl J Med. 2025; Hugosson J, Månsson M, Wallström J, et al. (GÖTEBORG-2). N Engl J Med. 2022;387(23):2126-2137; Bakker MF, de Lange SV, Pijnappel RM, et al. (DENSE). N Engl J Med. 2019;381(21):2027-2037; and Gao W, Wen CP, Wu A, Welch HG. JAMA Intern Med. 2022;182(3):302-310.
Medical Disclaimer: This resource provides clinical context for educational purposes and is not medical advice. Never delay or skip standard organ-specific cancer screening (colonoscopy, mammography, cervical screening, or evaluation of new symptoms) based on a negative blood test or commercial scan. Consult Dr. Ash or your own physician to personalize your screening plan.
Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Longevity

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start Your Intake

Frequently Asked Questions

Common Questions

No. In PATHFINDER 2 (Nabavizadeh et al., *Nature Medicine* 2026, n = 32,007), a negative Galleri test had a negative likelihood ratio (NLR) of 0.61, dropping 1-year cancer risk only from 1.4% (440 / 32,007) to 0.8% (267 / 31,720). That means 61% of all cancers found within 12 months happened in people who tested negative (~8 cancers missed for every ~5 found per 1,000 tested). In addition, Galleri spots zero precancerous colon polyps or cervical CIN (NordICC, Bretthauer *NEJM* 2022) and missed its Stage III-IV goal (IRR 1.03, P = 0.63) in the 142,250-person NHS-Galleri trial (Sasieni *NEJM* Oct 2026).
Across PATHFINDER 2 (n = 32,007) and NHS-Galleri (n = 142,250), specificity is 99.5% to 99.64% (~0.4% false-positive rate) and positive predictive value (PPV) is 45.8% to 60.3% (38.0% to 43.1% in the first PATHFINDER study). The test names the right organ of origin 91.1% to 93.6% of the time. When a positive signal turns out to be a false alarm, clearing it took a median of 162 days of scans and procedures in PATHFINDER (Schrag *Lancet* 2023).
Across pooled reviews (Kwee 2019; Ahsan *JGIM* 2026, n = 18,043; Martins da Fonseca *Eur Radiol* 2026, n = 9,024), out of every 1,000 healthy adults scanned, about 780 have an abnormal finding, 320 have a serious or unclear finding, and 150 have a non-cancer finding that triggers 86 follow-up workups and 31 procedures. Meanwhile, 14 to 16 are diagnosed with cancer (1.4% to 1.57%) and 28 (2.8%) can have false-negative scans (Basar 2021). In the 21,651-person MRI cohort by Wong et al. (*JAMA Network Open* 2026), 7.0% (~1,500 people) had incidental pancreatic cysts (only 0.08% > 3 cm), starting years of repeat scans.
While yearly LDCT cuts lung cancer deaths by 20% to 24% in heavy smokers (20+ pack-years, NLST / NELSON), zero randomized trials support LDCT in never-smokers (Kerpel-Fronius *JTO* 2022). Modeling shows that 6,162 average-risk never-smokers must be screened to prevent one lung cancer death versus 353 eligible smokers (Xu *Lancet Reg Health* 2026). In Taiwan's TALENT study (Chang *Lancet Respir Med* 2024), 96.5% of found cancers were Stage 0-I (mostly in situ), and broad CT screening in Taiwanese women caused a 6-fold jump in early diagnoses with zero drop in late cancer or deaths (Gao, Wen & Welch *JAMA Intern Med* 2022). In never-smokers, the #1 step is testing home basement radon (fix if >= 4.0 pCi/L, EPA).

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

Healthspan vs Lifespan: Why Living Longer Is Not Enough | Philadelphia

Healthspan vs Lifespan: Why Living Longer Is Not Enough | Philadelphia

Americans live to about 78 but spend the last 12 years sick and dependent. A Philadelphia primary care practice on why healthspan is the better metric.

Read Deep Dive
Medicine 3.0 Philadelphia | The Systems-Biology Model of Longevity

Medicine 3.0 Philadelphia | The Systems-Biology Model of Longevity

What Medicine 3.0 means and how a Philadelphia primary care practice uses it to extend healthspan rather than lifespan alone.

Read Deep Dive
Precision Nutrition Philadelphia | Medicine 3.0 Protein Leverage

Precision Nutrition Philadelphia | Medicine 3.0 Protein Leverage

Stop chasing weight loss. Optimize for muscle mass and metabolic flexibility with Medicine 3.0 nutrition. Led by Ashvin Vijayakumar MD.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

Share your numbers if you know them, your family history, and what you want to get ahead of. Dr. Ash reads every intake personally.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs